In a blow to its biggest rev­enue dri­ver, In­di­v­ior los­es patent bat­tle with gener­ics mak­er Alvo­gen

British drug­mak­er In­di­v­ior watched its stock tum­ble Fri­day morn­ing fol­low­ing news that it lost a patent dis­pute with a ri­val gener­ics drug­mak­er, com­pro­mis­ing In­di­v­ior’s grip on the opi­oid ad­dic­tion mar­ket.

The is­sue cen­ters on In­di­v­ior’s drug Sub­ox­one, which has long been tak­en as dai­ly strips that dis­solve on the tongue. The drug, which ac­counts for 80% of In­di­v­ior’s rev­enue, con­tains a mild opi­oid that helps stymie with­draw­al for opi­oid ad­dicts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER